A randomized, double-blind, placebo-controlled, multi-centre phase I trial investigating the safety of GRAZAX-R in children aged 5-12 years with grass pollen induced rhinoconjunctivitis (with/without asthma)

Trial Profile

A randomized, double-blind, placebo-controlled, multi-centre phase I trial investigating the safety of GRAZAX-R in children aged 5-12 years with grass pollen induced rhinoconjunctivitis (with/without asthma)

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Adverse reactions
  • Sponsors ALK-Abello
  • Most Recent Events

    • 01 Sep 2007 Results have been published
    • 05 May 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top